Cited by 660Estrogen and related hormone effectsNuclear Receptors and SignalingGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Open access

Lavinsky, Robert M., Jepsen, Kristen, Heinzel, Thorsten, Torchia, Joseph, Mullen, Tina-Marie, Schiff, Rachel, Del-Rio, Alfonso Leon, Ricote, Mercedes, Ngo, Sally, Gemsch, Joslin, Hilsenbeck, Susan G., Osborne, C. Kent, Glass, Christopher K., Rosenfeld, Michael G., Rose, David W.·1998·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.95.6.2920PMC PMC19670

Open this paper in CoChat — free account

Abstract

Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain. Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, positively or negatively, by diverse signal transduction pathways. Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer. Our data suggest that N-CoR- and SMRT-containing complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.

Integrity signals

Registry

Crossref · 10.1073/pnas.95.6.2920

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230

Show all 4 references

Research works printed but not linked: 46

10.1006/scel.1994.1015 · DOI
10.1038/377397a0 · DOI
10.1038/387043a0 · DOI
10.1128/MCB.16.10.5458 · DOI
J-W Lee, H-S Choi, J Gyuris, R Brent, D D Moore Mol Endocrinol 9, 243–254 (1995).
10.1038/377454a0 · DOI
T Matkovits, S Christakos Mol Endocrinol 9, 232–242 (1995).
10.1210/mend.11.7.9939 · DOI
10.1016/0960-0760(95)00084-D · DOI
10.1038/387049a0 · DOI
10.1073/pnas.93.23.12845 · DOI
10.1016/0092-8674(95)90355-0 · DOI
10.1016/0092-8674(95)90356-9 · DOI
10.1016/S0092-8674(00)80211-1 · DOI
10.1038/38664 · DOI · Paper page
10.1126/science.8197458 · DOI
10.1126/science.270.5240.1354 · DOI
10.1016/S0092-8674(00)81118-6 · DOI · Paper page
10.1038/42652 · DOI
10.1016/S0955-0674(97)80066-X · DOI
10.1038/370226a0 · DOI
10.1101/gad.8.8.869 · DOI
10.1038/384641a0 · DOI
10.1016/S0092-8674(00)82001-2 · DOI · Paper page
10.1038/382319a0 · DOI
C K Osborne, R M Elledge, S Fuqua Sci Am 3, 32–41 (1996).
10.1007/BF00666205 · DOI
10.1002/j.1460-2075.1993.tb05756.x · DOI
D Ignar-Trowbridge, C Teng, K Ross, M G Parker, K S Korach, J McLachlan Mol Endocrinol 7, 992–998 (1993).
10.1073/pnas.90.13.6120 · DOI
10.1002/j.1460-2075.1996.tb00571.x · DOI
10.1083/jcb.119.6.1405 · DOI
10.1093/jnci/83.20.1477 · DOI
10.1093/jnci/87.10.746 · DOI
W Seol, M J Mahon, Y K Lee, D D Moore Mol Endocrinol 10, 1646–1655 (1996).
10.1210/mend.11.6.0009 · DOI
N Fujimoto, B S Katzenellenbogen Mol Endocrinol 8, 296–304 (1994).
10.1074/jbc.270.16.9535 · DOI
10.1074/jbc.271.39.24172 · DOI
10.1073/pnas.89.22.10563 · DOI
M Tzukerman, A Esty, D Santiso-Mere, P Danielian, M G Parker, R Stein, J W Pike, D P McDonnell Mol Endocrinol 8, 21–30 (1994).
10.1126/science.274.5295.2100 · DOI
10.1101/gad.11.7.835 · DOI
10.1093/jnci/53.1.283 · DOI
10.1073/pnas.94.20.10762 · DOI
10.1126/science.279.5351.703 · DOI

Sorted by citations

Items 501–581 of 581

TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha
Romo, B. A., Karakyriakou, B., Cressey, L. E., Brauer, B. L., Yang, H.-J., Warren, A., Johnson, A. L., Kettenbach, A., & Miller, T. W. (2024) · Cancers · doi:10.3390/cancers16050845 · Cited by 5
“While the e ﬀ ects of NCOA3 (AIB1, SRC3) and NCOR2 (SMRT) on ER are well known [31,32], the e ﬀ ects of TRIM33 on ER have not yet been reported.”
Background
The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient.
Davezac, M., Meneur, C., Buscato, M., Zahreddine, R., Arnal, J., Dalenc, F., Lenfant, F., & Fontaine, C. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115677 · Cited by 5
Targeting mutated estrogen receptor alpha: Rediscovering old and identifying new therapeutic strategies in metastatic breast cancer treatment
Padrão, N., Mayayo‐Peralta, I., & Zwart, W. T. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.10.008 · Cited by 5
Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease
Chafin, C. B., Muse, S. J., Hontecillas, R., Bassaganya-Riera, J., Caudell, D., Shimp, S. K., Rylander, M., Zhang, J. Z. H., Li, L.-W., & Reilly, C. (2010) · Journal of Inflammation Research · doi:10.2147/jir.s13394 · Cited by 5
“Discussion The activation of PPAR-γ was originally shown to block the proinflammatory effects of lipopolysaccharide and various cytokines in both monocytes and macrophages by antagonizing the activities of AP-1, STAT, and NF-κB.(34,35) Specifically, activation of PPAR-γ decreased the production of nitric oxide, IL-6,…”
Cloning and functional characterization of a rat Daxx that functions as a corepressor for the androgen receptor
Mizuta, H., & Kuroda, Y. (2004) · Cell Biology International · doi:10.1016/j.cellbi.2004.05.006 · Cited by 5
“These factors were also found to serve as corepressors for the steroid receptor superfamily, including the progesterone (PR) and estrogen (ER) receptors (Jackson et al., 1997; Lavinsky et al., 1998; Smith et al., 1997), as well as AR (Dotzlaw et al., 2002; Fu et al., 2002; Liao et al., 2003).”
Background
Intranuclear trafficking of transcription factors: Requirements for vitamin D‐mediated biological control of gene expression
Stein, G. S., Lian, J. B., Stein, J. L., van Wijnen, A. J., Montecino, M. A., Javed, A., Pratap, J., Choi, J. Y., Zaidi, S. K., Gutierrez, S. E., et al. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10364 · Cited by 3
Physiological and pharmacological function of PPARs.
Takahashi, N., & Kawada, T. (2001) · Folia Pharmacologica Japonica · doi:10.1254/fpj.117.319 · Cited by 5
Transcriptional Corepressors: Mediators of Eukaryotic Gene Repression
Privalsky, M. (2001) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-10595-5 · Cited by 5
Deciphering the role of siRNA in anxiety and depression
Bale, R., & Doshi, G. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176868 · Cited by 3
Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions
Lee, D. H., Asare, B. K., & Rajnarayanan, R. V. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1220460 · Cited by 7
“The phosphorylation has an important role in recruiting coregulators of the ER, and thus enhances estrogen-triggered transcriptional activity.(9,10) In ERa and ERb, the DNA binding domain (DBD) is the most conserved domain; about 96% sequence homology.”
Background
What are comparative studies telling us about the mechanism of ERbeta action in the ERE-dependent E2 signaling pathway?
Li, X.-D., Huang, J., Fluharty, B. R., Huang, Y.-F., Nott, S. L., & Muyan, M. (2008) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.03.001 · Cited by 4
The fight against tamoxifen resistance in breast cancer therapy: a new target in the battle?
Nichols, M. (2007) · Molecular Interventions · doi:10.1124/mi.7.1.4 · Cited by 4
Novel approaches to controlling transcription.
Schaal, T. D., Holmes, M., Rebar, E., & Case, C. (2002) · Genetic engineering · doi:10.1007/978-1-4615-0721-5_7 · Cited by 4
Mechanical Disruption by Focused Ultrasound Re-sensitizes ER+ Breast Cancer Cells to Hormone Therapy.
Murad, H. Y., Sabol, R., Nyiramana, J., Twizeyimana, A., Bortz, E., Matossian, M., Hong, S. N., Kelly, C. A., Burow, M., Bunnell, B. A., et al. (2024) · Ultrasound in Medicine and Biology · doi:10.1016/j.ultrasmedbio.2024.08.015 · Cited by 3
Toxicity, cytotoxicity and biological activities of seeds of Carapa procera (DC), a native oil tree
Bayala, B., Sow, B., Millogo, V., Ouattara, Y., & Tamboura, H. (2019) · International Journal of Biological and Chemical Sciences · doi:10.4314/ijbcs.v13i1.5 · Cited by 3
“The other important, which can explain estrogen action was the discovery of co-activators (Onate et al., 1995) and co-repressors (Lavinsky et al., 1998), which are involved in the initiation and regulation of gene transcription by the ER.”
Background
Optimizing the Use of Neoadjuvant Endocrine Therapy
Agrawal, L., & Mayer, I. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0455-z · Cited by 3
The dark side of antihormonal action in breast cancer
Gee, J., Stone, A., Mcclelland, R., Hiscox, S., Hutcheson, I., Jordan, N., Fiegl, H., Widschwendter, M., Shaw, V., Barrow, D., et al. (2009) · doi:10.1007/978-1-4020-8526-0_4 · Cited by 3
Genetics and pharmacogenetics of estrogen response
Sala, S. C., Martineti, V., Carossino, A., & Brandi, M. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.4.503 · Cited by 3
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
Freddie, C. T., Christensen, G. L., & Lykkesfeldt, A. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.03.005 · Cited by 3
ARA67/PAT1 Functions as a Repressor To Suppress Androgen Receptor Transactivation
Zhang, Y.-Q., Yang, Y., Yeh, S., & Chang, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.1044-1057.2004 · Cited by 3
“Although nuclear receptor corepressor and silencing mediator of retinoid and thyroid hormone receptor (SMRT) were initially identified as corepressors to mediate active suppression by unliganded thyroid hormone receptor and retinoid acid receptor (6, 22), later studies suggest that they also serve as corepressors of p…”
Background
Eukaryotic conditional expression system.
Sourisseau, T., le Dréan, Y., Salbert, G., Flamant, F., & Michel, D. (1999) · BioTechniques · doi:10.2144/99271st03 · Cited by 3
Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer
Hiscox, S., Gee, J., & Nicholson, R. (2009) · Springer eBooks · doi:10.1007/978-1-4020-8526-0 · Cited by 3
Targeted mutation of key residues at the start of helix 12 in the hERalpha ligand-binding domain identifies the role of hydrogen-bonding and hydrophobic interactions in the activity of the protein.
Zhao, C., Abrams, J., & Skafar, D. F. (2006) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.06.036 · Cited by 3
Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER+ Breast Cancer
Bar, M., Widłak, W., & Vydra, N. (2026) · International Journal of Cancer · doi:10.1002/ijc.70522 · Cited by 2
Challenges and Opportunities of Genomic Approaches in Therapeutics Development
Gray, J. S., & Campbell, M. J. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0849-4_7 · Cited by 4
Hormone Therapy for Metastatic Breast Cancer
Kang, S. (2017) · doi:10.3904/kjm.2017.92.3.251 · Cited by 2
“하면 타목시펜 내성에 대한 원인으로 에스트로겐 수용체의 상실[32], ERα와 ERβ의 다양한 발현, CYP2D6 유전형의 변이 에 의한 활성화 대사물인 endoxifen의 혈중 농도 감소[33,34], 보조 억제 인자인 nuclear receptor corepressor가 감소, 보조 활 성 인자의 활성화 등[35,36]이 제안되나 에스트로겐 수용체 와 인간상피수용체-2 (HER-2)와의 crosstalk가 가장 주목받고 있다[37].”
Estrogen Receptor Pathways and Breast Cancer
Peng, J., & Jordan, V. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_9 · Cited by 2
“regions of RD2 and RD3 and are indicated below the structure [200, 202, 203].”
Background
Molecular insights into endocrine resistance.
Johnston, S. (2005) · doi:10.1016/s1359-6349(05)80279-4 · Cited by 2
Proteins Accompanying the Estrogen Receptor α and β: A Model for Studying Protein Hetero-Complexes
Jisa, E., Graumann, K., & Jungbauer, A. (2001) · Biocatalysis and Biotransformation · doi:10.3109/10242420108992028 · Cited by 2
Molecular Pharmacology of Estrogen and Progesterone Receptors
Sherk, A., & McDonnell, D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369443-0/50004-1 · Cited by 2
Estrogen receptors and anti-estrogen therapies.
Buluwela, L., Constantinidou, D., Pike, J., & Ali, S. (2004) · Cancer treatment and research · doi:10.1007/1-4020-7847-1_13 · Cited by 2
Transcriptional Control of the Development and Function of the Hypothalamic-Pituitary Axis
Parker, G. E., Sloop, K. W., & Rhodes, S. J. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-156-5_1
The Androgen Receptor
Jenster, G. W., Trapman, J., & Brinkmann, A. O. (2001) · Elsevier eBooks · doi:10.1016/b978-012146160-7/50005-6 · Cited by 3
Estrogen Action and Breast Cancer
Fox, J., Liu, H., & Jordan, V. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-664-5_10 · Cited by 2
Nuclear receptors: a pandora of hope for metabolic syndrome
Singh, S., & Agrawal, R. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2620694 · Cited by 1
TENT5C functions as a corepressor in the ligand‐bound glucocorticoid receptor and estrogen receptor α complexes
Li, Y., Perera, L., He, R. S., Baptissart, M., Petrovich, R. M., & Morgan, M. (2025) · FEBS Journal · doi:10.1111/febs.70137
“Coactivators and corepressors can be common to multiple receptors, which leads to crosstalk between different steroid hormone pathways [19 – 22].”
Neuroepigenetics of Sexual Differentiation of Brain and Behavior
McCarthy, M. M., Stockman, S. L., & Nugent, B. M. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-24493-8_9 · Cited by 2
Perinatal Neurohormonal Programming and Endocrine Disruption
Rosenfeld, C. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801383-0.00005-0 · Cited by 1
Chapter 127 – Estrogen and Progesterone Action
Weigel, N., & Smith, C. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00127-x · Cited by 1
Corepressors in Mediating Repression by Nuclear Receptors
Préfontaine, G. G., Cook, P. J., & Rosenfeld, M. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00245-x
Self-citation
Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer
Ali, S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-8526-0_2 · Cited by 1
“Firstly, Lavinsky et al. ( Lavinsky et al. 1998 ) showed that long-term treatment of MCF-7 cells transplanted in nude mice with tamoxifen, results in the development of tamoxifen-resistant tumours, the tumours being characterised by reduced levels of NCoR.”
Background
Mechanisms of Resistance to Hormone Therapy
Fuqua, S., & Cui, Y. (2006) · doi:10.1007/978-3-540-28266-2_37 · Cited by 1
Breast Cancer Chemoprevention by Selective Estrogen Receptor Modulators
Smith, C. L. (2004) · doi:10.1007/978-1-59259-767-3_16 · Cited by 1
Regulation of NF-кB by Glucocorticoids
Bosscher, K. D., Berghe, W. V., & Haegeman, G. (2003) · Springer eBooks · doi:10.1007/978-94-010-0163-2_10 · Cited by 1
Transcriptional regulation of cellular fatty acid homeostasis
van Bilsen, M. (2003) · Advances in molecular and cell biology · doi:10.1016/s1569-2558(03)33016-4 · Cited by 1
Applications of developmental biology to medicine and animal agriculture
Smith, R. C., & Rhodes, S. J. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8391-7_7 · Cited by 2
CHAPTER 1 – Molecular Pharmacology of Estrogen and Progesterone Receptors
McDonnell, D. (2000) · Elsevier eBooks · doi:10.1016/b978-012453790-3/50002-0 · Cited by 1
Development of steroidal molecules for targeted breast cancer therapy: Endocrine resistance and innovative drug design.
Dar, Z. A., & Bansal, R. (2026) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107097
Nucleic sexual hormone receptor signaling pathways in breast cancer: function regulation, crosstalk, and therapeutic implications
Zeng, K., Wang, A., Sun, H., Wang, C., Wang, C., Zou, R., Yang, D., Bai, Y., Wang, M., Xu, Y. Y., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01568-x
“…α torepress transcription, thereby mediating the inhibitory action of tamoxifen; notably, reduced N-CoR levels correlate with acquired tamoxifen resistance, underscoring the critical balance between coactivator and cor-epressor complexes in determining ER α signaling outcomes 180 (Fig.”
Structural Insights into Estrogen Receptors and Antiestrogen Therapies
de Vera, I. M. S., Wanninayake, U. S., & Burris, T. (2018) · Estrogen Receptor and Breast Cancer · doi:10.1007/978-3-319-99350-8_10
Méthodes bioinformatiques pour l'analyse de données de séquençage dans le contexte du cancer. (Bioinformatics methods for cancer sequencing data analysis)
Rudewicz, J. (2017) · doi:10.70675/465377aezef2fz4c26z9be6z5522c7056d79
“Par exemple, l'augmentation de l'expression de coactivateurs du récepteur aux ÷strogènes, tel que NCOA3 (Lavinsky et al., 1998) et MSH2 (Wada-Hiraike et al.”
Background
La 7β-hydroxy-épiandrostérone dans des modèles in vitro de cancer du sein : effets anti-estrogéniques et rôle des récepteurs des estrogènes
Niro, S. (2012) · theses.fr (ABES) · doi:10.70675/6d4b3bb2zc7adz43f3z857ez8de3c447fcfb
“…(Nuclear Co-Repressor) et SMRT (Silencing Mediator for Retinoid and Thyroid hormone receptor) interagissant avec le RE lié aux anti-estrogènes et acteurs de l’inhibition de la transcription par le 4-hydroxytamoxifène et le raloxifène (Shang et Brown, 2002; Shang et al, 2000 ; Lavinsky et al, 1998).”
Background
Investigation of the mechanisms of estrogen receptor activation by phosphorylation
Halliday, A. C. (2009) · Spiral (Imperial College London) · doi:10.25560/4348
Changes of Coregulators, MAP Kinase Activity and p27/kip1 with Estrogen or Antiestrogen Treatment in Breast Cancer Cell Line
Park, S., Heo, M., Lee, M. J., Kim, J. H., & Park, B. (2008) · doi:10.4048/jbc.2008.11.2.56
“(12)한편coactivator와반대로타목시펜치료중corepressor의감소역시타목시펜저항성과관계될수있다.(13) 성장인자수용체HER2 및에스트로겐수용체동시과발현유 방암의 경우 예후가 불량하고,(14, 15) 그 기전의 하나는 ERHER2 신호전달의상호교차(cross talk)로인한세포증식의증 가와 타목시펜 저항성 발생으로 제기되고 있다.”
Role of PELP1 in EGFR-ER Signaling Crosstalk in Ovarian Cancer Cells
Vadlamudi, R. (2008) · doi:10.21236/ada509754
Antihormonal Therapy for Breast and Prostate Cancer
Cordera, F., & Jordan, V. C. (2007) · doi:10.1002/9780470025079.chap92.pub2
Sequential Adjuvant Hormone Therapy in Postmenopausal Breast Cancer: Rationale and Clinical Results
Longo, R., D'Andrea, M., & Gasparini, G. (2006) · doi:10.1177/172460080602100207
“Like ER CoAs, CoR action is also regulated by multiple signal transduction pathways (12).”
Background
Sequential adjuvant hormone therapy in postmenopausal breast cancer: rationale and clinical results.
Longo, R., D'Andrea, M., & Gasparini, G. (2006) · International Journal of Biological Markers · doi:10.5301/jbm.2008.3523
Einblicke in die Entstehung der Tamoxifen-Resistenz
Schem, C., Bauerschlag, D., Mundhenke, C., & Maass, N. (2005) · Gynäkologische Endokrinologie · doi:10.1007/s10304-005-0108-7
The impact of the Women's Health Initiative on the search for improved treatments for the conditions associated with long-term oestrogen deprivation
McDonnell, D., & Miranda, P. J. (2003) · doi:10.1258/136218003323023364
The Breast Cancer Phenotype and Endocrine Response: Implications for New Drug Development Initiatives
Gee, J., & Nicholson, R. (2002) · CRC Press eBooks · doi:10.1201/b14039-12
Prediction of interaction partners for orphan nuclear receptors by prior‐based protein sequence profiles
Nagl, S., Das, S., & Smith, T. (2000) · Journal of Molecular Recognition · doi:10.1002/1099-1352(200005/06)13:3
Thyroid Hormone Receptor Family Members: Homodimers, Heterodimers, and Mechanisms of Transcriptional Repression
Cohen, R., & Wondisford, F. (2000) · doi:10.1385/1-59259-221-x:135
Role of MIR-29B-1 and MIR-29A in endocrine-resistant breast cancer.
Muluhngwi, P. (2017) · doi:10.18297/etd/2714
Tamoxifen: Mechanisms of Resistance
Adams, C. M. (2010) · doi:10.21007/etd.cghs.2010.0004 · Cited by 1
“NCoR binds avidly to ER in the presence of tamoxifen, but when NCoR activity is blocked with an antibody in MCF-7 human breast cancer cells, tamoxifen instead acts as an agonist [49].”
Background
Modulation of Soluble Receptor Signaling by Coregulators
Flaveny, C. A., Kumar, M., & Perdew, G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00212-8
New Molecular Therapeutic Interventions: The Case of Breast Cancers
Marsaud, V., & Renoir, J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_17
Ligand-independent activation of steroid hormone receptors by gonadotropin-releasing hormone
Chen, J.-L. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071874
Endocrine Resistance in Breast Cancer- Where Are We NowWith Intelligent Combination Therapies?
Johnston, S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-8526-0_10
CHAPTER 14 – Regulation of Bone Cell Function by Estrogens
Komm, B., Cheskis, B., & Bodine, P. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50016-1
Hormono-sensibilité et hormonorésistance aux anti-estrogènes et inhibiteurs d’aromatase
de Cremoux, P. (2006) · doi:10.1007/2-287-31109-2_21
1–38 Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator
Brown, P. (2005) · doi:10.1016/s1043-321x(05)80059-1
Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
Fabian, C., Kimler, B., Anderson, J., Tawfik, O., & Mayo, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1015
CHAPTER 274 – Corepressors in Mediating Repression by Nuclear Receptors
Jepsen, K., & Rosenfeld, M. (2003) · Elsevier eBooks · doi:10.1016/b978-012124546-7/50636-7
Self-citation
CHAPTER 2B – The Normal Human Ovary Part II: How Steroid Hormones Work
Kase, N. (2003) · Elsevier eBooks · doi:10.1016/b978-012053642-9/50007-7
Insights into the Molecular Mechanism of SERMs Through New Laboratory Models
Gajdos, C., Zapf, J., & Jordan, V. (2002) · doi:10.1007/978-1-59259-157-2_8
SERM Modulation of Gene Expression
Webb, P. (2002) · doi:10.1007/978-1-59259-157-2_4
Androgen Receptor Interacting Proteins: Co-Activators And Co-Repressors
Heinlein, C., Sampson, E., & Chang, C. (2002) · Springer eBooks · doi:10.1007/978-1-4615-1161-8_4
Estrogen and Antiestrogen Actions on Human Prostate Cancer: A Dissertation
Lau, K.-M. (2001) · doi:10.13028/dfry-ga14
Regulation of Nuclear Hormone Receptors by Corepressors and Coactivators: a Dissertation
Wu, X. (2001) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/h387-xd16
Molecular and genetic analysis of JIL-1, a chromatin associated protein kinase implicated in transcriptional regulation in Drosophila
Jin, Y. (1999) · doi:10.31274/rtd-180813-13477
“In the case of corepressor, the interaction between antagonist-bound ER and NcoR is significantly weakened by activation of the cAMP pathway (Lavinsky et al., 1998).”
Background

Authors: Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., & Rose, D. W.
Affiliations: Howard Hughes Medical Institute (US)
Howard Hughes Medical Institute, Cellular and Molecular Medicine, Whittier Diabetes Program, and UCSD Graduate Program in Biology, Department and School of Medicine, University of California at San Diego, La Jolla, CA 92093-0648; and Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284-7884
Corresponding author: Rose, David W.
ORCID: Jepsen, Kristen
Heinzel, Thorsten
Torchia, Joseph
Mullen, Tina-Marie
Schiff, Rachel
Ricote, Mercedes
Hilsenbeck, Susan G.
Osborne, C. Kent
Glass, Christopher K.
Rosenfeld, Michael G.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 1998-03-17
Volume: 95
Issue: 6
Pages: 2920-2925
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.95.6.2920
PMC: PMC19670
OpenAlex: W2128003724
Cited by: 660
References: 52
Citations by year: 2026: 5 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 10 · 2021: 6 · 2020: 10 · 2019: 13 · 2018: 10 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 13 · 2013: 12 · 2012: 20
FWCI: 30.37
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Science Foundation
Howard Hughes Medical Institute
American Diabetes Association
National Institutes of Health
National Cancer Institute (P30CA 54174, P30CA054174, P50 CA58183, P50CA058183)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: nuclear receptor corepressor, SMRT, signaling pathways, retinoic acid receptor, estrogen receptor, tamoxifen resistance, breast cancer, transcriptional repression, ligand-dependent transcription, CREB-binding protein, coactivator complexes
MeSH terms: Animals, Breast Neoplasms, Disease Models, Animal, DNA-Binding Proteins, Drug Resistance, Estrogen Antagonists, Gene Expression Regulation, Humans, Models, Biological, Nuclear Proteins, Protein Binding, Protein Kinases, Receptors, Estrogen, Repressor Proteins, Tamoxifen, Signal Transduction, Genes, Reporter, Receptors, Retinoic Acid, Mice, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Co-Repressor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks